India’s quick commerce race is intensifying, with Blinkit, Zepto and Swiggy Instamart competing for dominance. Blinkit leads in orders, revenue, dark store count and is the only player with positive EBITDA. Zepto stands out for the highest orders per store…
Cipla said the USFDA has classified its April inspection of the company’s Goa manufacturing facility as Voluntary Action Indicated (VAI), a status under which observations are expected to be addressed voluntarily without regulatory action.
One of the biggest drags on the benchmark indices was the IT sector. The Nifty IT index extended its losing streak to seven straight sessions, with all constituent stocks ending in the red. Infosys was among the major contributors to…
NLC India signs MoU with CSIR-CECRI to develop tech for extracting rare earths from mine waste, supporting India’s critical minerals self-reliance mission.
MTAR Technologies shares fell after Crusoe Energy paused a 1.8 GW data centre project that was expected to deploy 900 MW of Bloom Energy fuel cells. Bloom Energy accounts for an estimated 55%-65% of MTAR’s revenue.
With the latest approval, Alembic Pharma’s cumulative USFDA tally stands at 241 ANDA approvals, comprising 221 final approvals and 20 tentative approvals.
Sanjay Parekh of Sohum Asset Managers sees potential in CarTrade Tech, large private banks and select infrastructure plays. While he remains constructive on India’s manufacturing story, he believes valuations in the EMS sector are demanding and warrant caution. He also…
Hetal Dalal, President & COO of IiAS and Shriram Subramanian, Founder & MD of InGovern why investors may demand greater clarity on the use of funds, the identity of potential investors and Zee’s long-term growth strategy before approving the proposal.
Ankur Rudra, Head of APAC Telecoms & India TMT Research at JPMorgan, expects first-quarter growth estimates to be lowered by 0.5-1 percentage point, which points to a relatively subdued year for the sector.
The approval expands the eligible patient population for the therapy in India and allows AstraZeneca to market the drug for the additional indication, subject to any other required statutory clearances.